Provided by Tiger Trade Technology Pte. Ltd.

Voyager Therapeutics

3.39
-0.0009-0.03%
Volume:163.15K
Turnover:545.49K
Market Cap:208.83M
PE:-1.87
High:3.40
Open:3.39
Low:3.24
Close:3.39
52wk High:5.55
52wk Low:2.94
Shares:61.62M
Float Shares:44.40M
Volume Ratio:0.57
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8121
EPS(LYR):-2.0400
ROE:-54.09%
ROA:-27.34%
PB:1.35
PE(LYR):-1.66

Loading ...

Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist

TIPRANKS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX)

TIPRANKS
·
Aug 10

Voyager Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 10

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 10

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

TIPRANKS
·
Aug 07

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Reuters
·
Aug 07

Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M Estimate

Benzinga Earnings
·
Aug 07

Voyager Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

Voyager Therapeutics reports Q2 EPS (40c), consensus (51c)

TIPRANKS
·
Aug 07

Voyager Q2 FY26 Net Loss Narrows to $24.47 Million; Revenue Falls to $3.17 Million

Reuters
·
Aug 07

Voyager Therapeutics Q2 Net Income USD -24.473 Million

THOMSON REUTERS
·
Aug 07

Voyager Therapeutics Inc Expected to Post a Loss of 48 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Biogen's Alzheimer's Drug Lowers Toxic Protein, but Results were Mixed

Reuters
·
Jul 14

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Axsome Therapeutics (AXSM) and Nurix Therapeutics (NRIX)

TIPRANKS
·
Jul 14

Voyager Therapeutics advances tau-silencing gene therapy program

TIPRANKS
·
Jul 14

Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2

MT Newswires Live
·
Jul 13

Voyager Wins FDA IND Clearance for Alzheimer’s Gene Therapy Vy1706

Reuters
·
Jul 13

Voyager Demonstrates Single Iv Dose of Vy1706 Well Tolerated, Reduced Tau in 6-month Glp Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

THOMSON REUTERS
·
Jul 13

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?

Dow Jones
·
Jul 13

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jul 06